GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » PS Ratio

Q32 Bio (Q32 Bio) PS Ratio : (As of May. 22, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Q32 Bio's share price is $30.10. Q32 Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.23. Hence, Q32 Bio's PS Ratio for today is .

The historical rank and industry rank for Q32 Bio's PS Ratio or its related term are showing as below:

During the past 3 years, Q32 Bio's highest PS Ratio was 92.27. The lowest was 53.75. And the median was 70.95.

QTTB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.305
* Ranked among companies with meaningful PS Ratio only.

Q32 Bio's Revenue per Sharefor the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.23.

During the past 12 months, the average Revenue per Share Growth Rate of Q32 Bio was -200.00% per year.

Back to Basics: PS Ratio


Q32 Bio PS Ratio Historical Data

The historical data trend for Q32 Bio's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio PS Ratio Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Q32 Bio's PS Ratio

For the Biotechnology subindustry, Q32 Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's PS Ratio distribution charts can be found below:

* The bar in red indicates where Q32 Bio's PS Ratio falls into.



Q32 Bio PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Q32 Bio's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=30.10/-1.229
=

Q32 Bio's Share Price of today is $30.10.
Q32 Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Q32 Bio  (NAS:QTTB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Q32 Bio PS Ratio Related Terms

Thank you for viewing the detailed overview of Q32 Bio's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio (Q32 Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus